Cargando…

The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study

BACKGROUND: Bariatric surgery improves insulin sensitivity and secretion in patients with type 2 diabetes, but the effect on patients with prediabetes or even normal glucose tolerance deserves further consideration. METHODS: Cohort study including patients operated with laparoscopic Roux-en-Y gastri...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenberg, Erik, Rask, Eva, Szabo, Eva, Näslund, Ingmar, Ottosson, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378103/
https://www.ncbi.nlm.nih.gov/pubmed/32314253
http://dx.doi.org/10.1007/s11695-020-04599-w
_version_ 1783562342315851776
author Stenberg, Erik
Rask, Eva
Szabo, Eva
Näslund, Ingmar
Ottosson, Johan
author_facet Stenberg, Erik
Rask, Eva
Szabo, Eva
Näslund, Ingmar
Ottosson, Johan
author_sort Stenberg, Erik
collection PubMed
description BACKGROUND: Bariatric surgery improves insulin sensitivity and secretion in patients with type 2 diabetes, but the effect on patients with prediabetes or even normal glucose tolerance deserves further consideration. METHODS: Cohort study including patients operated with laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) between November 2012 and June 2017 at the Örebro University Hospital (n = 813) with follow-up of 742 patients 2 years after surgery. Fasting insulin, glucose, glycosylated hemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR) were analyzed at baseline and 2 years after surgery for patients with overt type 2 diabetes, prediabetes, or non-diabetes. RESULTS: Fasting insulin levels improved for all groups (diabetics baseline 25.5 mIU/L, IQR 17.5–38.0, 2 years 7.6 mIU/L, IQR 5.4–11.1, p < 0.001; prediabetics baseline 25.0 mIU/L, IQR 17.5–35.0, 2 years 6.7mIU/L, IQR 5.3–8.8, p < 0.001; non-diabetics baseline 20.0 mIU/L, IQR 14.0–30.0, 2 years 6.4 mIU/L, IQR 5.0–8.5, p < 0.001). HbA1c improved in all groups (diabetics baseline 56 mmol/mol, IQR 49–74 [7.3%, IQP 6.6–8.9], 2 years 38 mmol/mol, IQR 36–47 [5.6%, IQR 5.4–6.4], p < 0.001; prediabetics baseline 40 mmol/mol, IQR 39–42 [5.8%, IQR5.7–6.0], 2 years 36 mmol/mol, IQR 34–38 [5.5%, IQR 5.3–5.6], p < 0.001; non-diabetics baseline 35 mmol/mol, IQR 33–37 [5.4%, IQR 5.2–5.5]; 2 years 34 mmol/mol, IQR 31–36 [5.3%, IQR 5.0–5.4], p < 0.001). HOMA-IR improved in all groups (diabetics baseline 9.3 mmol/mol, IQR 5.4–12.9, 2 years 1.9 mmol/mol, IQR 1.4–2.7, p < 0.001; prediabetics baseline 7.0 mmol/mol, IQR 4.3–9.9, 2 years 1.6 mmol/mol, IQR 1.2–2.1, p < 0.001; non-diabetics 4.9 mmol/mol, IQR 3.4–7.3, 2 years 1.4 mmol/mol, IQR 1.1–1.9, p < 0.001). CONCLUSION: Insulin homeostasis and glucometabolic control improve in all patients after LRYGB, not only in diabetics but also in prediabetics and non-diabetic obese patients, and this improvement is sustained 2 years after surgery.
format Online
Article
Text
id pubmed-7378103
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-73781032020-08-04 The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study Stenberg, Erik Rask, Eva Szabo, Eva Näslund, Ingmar Ottosson, Johan Obes Surg Original Contributions BACKGROUND: Bariatric surgery improves insulin sensitivity and secretion in patients with type 2 diabetes, but the effect on patients with prediabetes or even normal glucose tolerance deserves further consideration. METHODS: Cohort study including patients operated with laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) between November 2012 and June 2017 at the Örebro University Hospital (n = 813) with follow-up of 742 patients 2 years after surgery. Fasting insulin, glucose, glycosylated hemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR) were analyzed at baseline and 2 years after surgery for patients with overt type 2 diabetes, prediabetes, or non-diabetes. RESULTS: Fasting insulin levels improved for all groups (diabetics baseline 25.5 mIU/L, IQR 17.5–38.0, 2 years 7.6 mIU/L, IQR 5.4–11.1, p < 0.001; prediabetics baseline 25.0 mIU/L, IQR 17.5–35.0, 2 years 6.7mIU/L, IQR 5.3–8.8, p < 0.001; non-diabetics baseline 20.0 mIU/L, IQR 14.0–30.0, 2 years 6.4 mIU/L, IQR 5.0–8.5, p < 0.001). HbA1c improved in all groups (diabetics baseline 56 mmol/mol, IQR 49–74 [7.3%, IQP 6.6–8.9], 2 years 38 mmol/mol, IQR 36–47 [5.6%, IQR 5.4–6.4], p < 0.001; prediabetics baseline 40 mmol/mol, IQR 39–42 [5.8%, IQR5.7–6.0], 2 years 36 mmol/mol, IQR 34–38 [5.5%, IQR 5.3–5.6], p < 0.001; non-diabetics baseline 35 mmol/mol, IQR 33–37 [5.4%, IQR 5.2–5.5]; 2 years 34 mmol/mol, IQR 31–36 [5.3%, IQR 5.0–5.4], p < 0.001). HOMA-IR improved in all groups (diabetics baseline 9.3 mmol/mol, IQR 5.4–12.9, 2 years 1.9 mmol/mol, IQR 1.4–2.7, p < 0.001; prediabetics baseline 7.0 mmol/mol, IQR 4.3–9.9, 2 years 1.6 mmol/mol, IQR 1.2–2.1, p < 0.001; non-diabetics 4.9 mmol/mol, IQR 3.4–7.3, 2 years 1.4 mmol/mol, IQR 1.1–1.9, p < 0.001). CONCLUSION: Insulin homeostasis and glucometabolic control improve in all patients after LRYGB, not only in diabetics but also in prediabetics and non-diabetic obese patients, and this improvement is sustained 2 years after surgery. Springer US 2020-04-20 2020 /pmc/articles/PMC7378103/ /pubmed/32314253 http://dx.doi.org/10.1007/s11695-020-04599-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Contributions
Stenberg, Erik
Rask, Eva
Szabo, Eva
Näslund, Ingmar
Ottosson, Johan
The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title_full The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title_fullStr The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title_full_unstemmed The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title_short The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study
title_sort effect of laparoscopic gastric bypass surgery on insulin resistance and glycosylated hemoglobin a1c: a 2-year follow-up study
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378103/
https://www.ncbi.nlm.nih.gov/pubmed/32314253
http://dx.doi.org/10.1007/s11695-020-04599-w
work_keys_str_mv AT stenbergerik theeffectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT raskeva theeffectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT szaboeva theeffectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT naslundingmar theeffectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT ottossonjohan theeffectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT stenbergerik effectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT raskeva effectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT szaboeva effectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT naslundingmar effectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy
AT ottossonjohan effectoflaparoscopicgastricbypasssurgeryoninsulinresistanceandglycosylatedhemoglobina1ca2yearfollowupstudy